Oral Drug Live Lab
A rare, candid conversation with Harvey Berger on building—and rebuilding—companies at the cutting edge of science. From pioneering cancer therapies to shaping the next generation of biotech leadership, his journey will inspire, challenge, and equip you to think bigger about what’s possible in drug development.
Expect hard-won lessons on leading through uncertainty, aligning teams through pivots, and developing leaders who can scale ideas from concept to clinic.
The Fireside Chat ignites the stage with Boston’s biotech trailblazers in a raw, no-filter conversation about what’s driving transformation right now. Expect bold perspectives, unvarnished lessons, and breakthrough ideas that challenge the status quo and spark new possibilities. This is where the energy peaks, the insights get real, and the future of drug development takes shape in front of you.
Moving from Biotech Startup to Operational Excellence
Scaling up isn’t just about headcount and funding—it’s about bringing in the right people at the right time. This session dives into how leaders can protect and evolve corporate culture while building organizations that move fast without losing focus. Hear candid insights from executives who have lived the tension between growth and culture, and learn what it really takes to scale with strength and stability.
Biopharmaceutical deals with Asian partners have long centered on services, with Asian firms as providers and US/EU sponsors as innovators. That pattern is shifting: more Asian companies now lead with novel pipelines and pursue innovation-led licensing and M&A.
Expect guidance on scouting and diligence; deal structures; IP and data protection; and co-development models that transfer know-how.
How policy, market perception, and macroeconomic pressure are reshaping the biotech investment landscape.
Fundraising looks different this cycle. Fundraising looks different this cycle. Many are insulated from broader market swings, so headlines can mislead. From a macro vantage, this panel shows where capital is actually flowing—and what it means for timing, milestones, and deal structure amid market and political noise.
“As Heraclitus once opined, ‘Change is the only constant.’”
Few areas in drug development are more impacted—and more impactful—than the supply chain, where logistics remain in flux amid tariff pressure and reshoring.
This discussion examines regional risk, dual sourcing, tech-enabled visibility, and how to future-proof material and manufacturing plans when “normal” keeps shifting.
Step inside the real-world challenges of getting clinical trials off the ground and why so many are happening outside the U.S. Our expert panel pulls no punches as they unpack the hidden pitfalls, regulatory hurdles, and operational missteps that can derail even the most promising programs, while sharing the strategies that can turn setbacks into successful, on-time launches.
Our cross-functional panel looks past the buzz to where AI is already earning time back through predictive modeling, smarter trial design, and faster decision cycles. Hear from leaders across the industry and discover how AI is already transforming the way we discover, develop, and deliver new therapies.
Learn what’s working, what isn’t, and how to scope AI use cases that move real endpoints.
